Đánh giá hiệu quả điều trị ung thư phổi không tế bào nhỏ giai đoạn IV bằng phác đồ gemcitabine cisplatin tại bệnh viện phổi trung ương

B GIO DC V O TO B Y T TRNG I HC Y H NI NGUYN THANH DNG ĐáNH GIá KếT QUả ĐIềU TRị UNG THƯ PHổI KHÔNG Tế BàO NHỏ GIAI ĐOạN IV BằNG PHáC Đồ GEMCITABINE & CISPLATIN TạI BệNH VIệN PHổI TRUNG ƯƠNG Chuyờn ngnh : Ung th Mó s : 60720149 LUN VN THC S Y HC Ngi hng dn khoa hc: PGS.TS Lấ TRUNG TH H NI - 2016 LI CM N Vi tt c lũng kớnh trng v s bit n chõn thnh, nhõn dp hon thnh bn lun ny, tụi xin c by t lũng bit n sõu sc nht ti: Ban giỏm hiu, Phũng o to sau i hc, B mụn Ung th Trng i hc Y H Ni Ban giỏm c, Phũng k hoch tng hp Bnh vin PHI TRUNG NG ó giỳp v to mi iu kin thun li cho tụi quỏ trỡnh hc v hon thnh lun ny Tụi xin chõn thnh cm n PGS TS Lấ TRUNG TH, ngi thy trc tip hng dn lun vn, ó tn tỡnh giỳp , ch bo v ng viờn tụi sut quỏ trỡnh nghiờn cu v hon thnh lun Thy dy tụi khụng ch kin thc chuyờn mụn m c o c ngh nghip, phng phỏp lun khoa hc Xin cm n th cỏc Bỏc s v nhõn viờn Khoa Ung bu Bnh vin Phi trung ng ó giỳp tụi quỏ trỡnh hc Xin chõn thnh cm n cụng sinh thnh, dng dc ca cha m;cm n nhng ngi thõn gia ỡnh ó sỏt cỏnh cựng tụi, giỳp , ng viờn v to mi iu kin cho tụi nhng nm hc va qua Tụi xin cm n bn bố, ng nghip ó giỳp , ng viờn tụi cú th hon thnh lun ny H Ni, ngy 10 thỏng 10 nm 2016 NGUYN THANH DNG LI CAM OAN Tụi l NGUYN THANH DNG, hc viờn cao hc khúa 23, chuyờn ngnh Ung th, Trng i hc Y H Ni xin cam oan: õy l lun bn thõn tụi trc tip thc hin di s hng dn ca Thy PGS TS Lấ TRUNG TH Cụng trỡnh ny khụng trựng lp vi bt k nghiờn cu no khỏc ó c cụng b ti Vit Nam Cỏc s liu v thụng tin nghiờn cu l hon ton chớnh xỏc, trung thc v khỏch quan, ó c xỏc nhn v chp nhn ca c s ni nghiờn cu cho phộp ly s liu v xỏc nhn Tụi xin hon ton chu trỏch nhim v nhng cam kt ny H Ni, ngy 10 thỏng 10 nm 2016 Ngi vit cam oan NGUYN THANH DNG CC CH VIT TT ASCO : Hip hi lõm sng ung th quc gia M (American society of clinical oncology) BN : Bnh nhõn CEA : (Carcino Embryonic Antigan ).Khỏng nguyờn biu mụ phụi AJCC : (American Joint Commitee on Cancer ) Hip hi Ung th M CK : Chu k CS : Cng s : ỏp ng G : Giai on ECOG : Liờn hip hi ung th hc phớa ụng (Eastern Cooperative Oncology Group) KPS : Ch s ton trng Karnofski MBH : Mụ bnh hc UICC : U ban phũng chng ung th quc t (Union International Contre la Cancer) UT : Ung th UTBM : Ung th biu mụ UTP : Ung th phi UTPKTBN : Ung th phi khụng t bo nh UTPTBN : Ung th phi t bo nh WHO : T chc Y t th gii (World Health Orgnization) SWOG : Hi ung th hc Tõy nam (Southwest Oncology Group) MC LC T VN CHNG TNG QUAN 1.1 DCH T HC V MT S YU T NGUY C CA UTP 1.1.1 Dch t hc 1.1.2 Mt s yu t nguy c 1.2 TRIU CHNG LM SNG V CN LM SNG 1.2.1 Triu chng lõm sng 1.2.2 Cn lõm sng 10 1.2.3 Chn oỏn xỏc nh 17 1.3 Chn oỏn giai on 17 1.4 CC PHNG PHP IU TR UNG TH PHI 19 1.4.1 iu tr theo giai on 21 1.4.2 iu tr húa cht giai on IIIB-IV 24 1.4.3 Chin lc mi iu tr UTPKTBN 28 1.5 MT S HểA CHT ANG S DNG 29 1.5.1 Gemcitabine 29 1.5.2 Cisplatin 30 CHNG 33 I TNG V PHNG PHP NGHIấN CU 33 2.1 I TNG NGHIấN CU 33 2.1.1 Tiờu chun la chn 33 2.1.2 Tiờu chun loi tr 33 2.2 PHNG PHP NGHIấN CU 34 2.2.1 Thit k nghiờn cu 34 2.2.2 C mu v chn mu 34 2.2.3 Cỏc bin s nghiờn cu 34 2.2.4 Mt s ch tiờu ỏnh giỏ 36 2.2.5 Quy trỡnh tin hnh nghiờn cu 39 2.5 X Lí S LIU 41 2.6 o c nghiờn cu 41 CHNG 44 KT QU NGHIấN CU 44 3.1 MT S C TRNG C NHN I TNG NGHIấN CU 44 3.1.1 Phõn b ngi bnh theo gii 44 3.1.2 Phõn b ngi bnh theo nhúm tui 44 3.1.3 Tỡnh trng hỳt thuc 44 3.2 Triu chng lõm sng 45 3.3 Triu chng cn lõm sng 47 3.4 ỏp ng iu tr 50 3.5 TC DNG KHễNG MONG MUN CA PHC 50 3.6 THI GIAN SNG THấM 51 Chng 54 BN LUN 54 4.1 V PHN B BNH NHN THEO NHểM TUI V GII 54 4.2 TèNH TRNG HT THUC 55 4.3 THI GIAN Cể TRIU CHNG U TIấN N LC NHP VIN 56 4.4 TRIU CHNG LM SNG 57 4.5 CN LM SNG 58 4.6 Mễ BNH HC 60 4.7 KT QU IU TR 60 4.7.1 T l ỏp ng 61 4.7.2 Thi gian sng thờm 61 4.8 TC DNG KHễNG MONG MUN CA HểA TR 63 KT LUN 66 KHUYN NGH 67 TI LIU THAM KHO PH LC DANH MC BNG Bng 1.1 t bin gen UTPKTBN Bng 1.2 Bng phõn loi cỏc typ mụ hc ung th biu mụ phi ca TCYTTG 2014 16 Bng 1.3: ỏnh giỏ giai on bnh 19 Bng 1.4: Mt s th nghim lõm sng so sỏnh phỏc Gemcitabine kt hp Cisplatin hoc Carboplatin vi cỏc phỏc khỏc 27 Bng 3.1 Phõn b ngi bnh theo nhúm tui 44 Bng 3.2 Tỡnh trng hỳt thuc 45 Bng 3.3 Thi gian hỳt thuc 45 Bng 3.4 Lý vo vin 45 Bng 3.5 Thi gian cú triu chng u tiờn n nhp vin 46 Bng 3.6 V trớ u trờn phim CT 48 Bng 3.7 Tỡnh trng di cn hch trung tht 48 Bng 3.8 Hỡnh nh tn thng qua ni soi ph qun 48 Bng 3.9 T l cỏc typ mụ bnh hc 48 Bng 3.10 Phõn b bnh nhõn theo s liu iu tr húa cht 49 Bng 3.11 T l ỏp ng theo typ mụ bnh hc 50 Bng 3.12 Tỏc dng khụng mong mun ca húa cht trờn h to mỏu 50 Bng 3.13 Tỏc dng khụng mong mun ca húa cht ngoi h to mỏu 51 Bng 4.1 So sỏnh vi kt qu th nghim ngu nhiờn ca cỏc tỏc gi 62 DANH MC BIU Biu 1.1 T l mc UTP trờn th gii nm 2012 Biu 1.2 T l t vong UTP trờn th gii nm 2012 Biu 3.1 Phõn b ngi bnh theo gii tớnh 44 Biu 3.2 Phõn b bnh nhõn theo hi chng ca bnh 46 Biu 3.3 Phõn b bnh nhõn theo triu chng ton thõn 47 Biu 3.4 T l bnh nhõn sỳt cõn 47 Biu 3.5 T l v trớ u hai phi 47 Biu 3.6 T l ỏp ng iu tr 50 Biu 3.7 Thi gian sng thờm ton b 52 Biu 3.8 Thi gian sng thờm theo tỡnh trng hỳt thuc 52 Biu 3.9 Thi gian sng thờm theo gii 53 Biu 3.10.Thi gian sng thờm theo typ mụ bnh 53 T VN Ung th phi (UTP) l loi ung th ph bin nht trờn ton cu ng thi cng l nguyờn nhõn gõy t vong hng u ung th T l mc ung th phi rt khỏc bit gia cỏc nc v ch cú 15,6% s bnh nhõn sng qua nm k t phỏt hin bnh Theo Globocan 2012, ton th gii cú khong 1,8 triu ngi mi mc UTP v khong 1,6 triu ngi cht vỡ cn bnh ny Vit Nam, cng theo Globocan 2012 nc ta cú 21865 ngi mi mc UTP chim 24.4 % tng s ca mi mc ung th v 19559 ngi cht vỡ UTP chim 21,8% Theo phõn loi ca T chc y t th gii, UTP c chia lm nhúm chớnh l ung th phi khụng t bo nh (UTPKTBN) v ung th phi t bo nh (UTPTBN), ú UTPKTBN chim 80 - 85% UTP l bnh cú ỏc tớnh cao, tin trin nhanh, di cn sm vo nhiu tng nh gan, xng, nóo bi th tiờn lng xu Triu chng lõm sng ca bnh li nghốo nn, khụng c hiu, d nhm ln vi bnh khỏc Do vy dự ó cú nhiu tin b chn oỏn nhng phn ln bnh nhõn (khong 70%) n vin giai on mun, khụng th iu tr bng phu thut Lỳc ny, vic ỏnh giỏ mc lan trn ca bnh la chn phỏc iu tr hp lý l rt quan trng Trong iu tr ung th phi, phu thut l phng phỏp hiu qu nht i vi giai on tn thng cũn khu trỳ lng ngc Húa cht v x tr l nhng phng phỏp c ỏp dng bnh giai on mun hn Trc thp k 80, iu tr húa cht cho bnh nhõn UTPKTBN giai on mun rt kộm hiu qu v nhiu tỏc dng ph T khong hn mt thp k nay, s i ca cỏc tỏc nhõn th h th ba nh Taxane, Gemcitabine, Vinorelbine ó m nhiu hy vng kh quan hn iu tr húa cht UTPKTBN giai on IV Sau ú nhiu nghiờn cu phi hp cỏc thuc mi 66 KT LUN Da trờn cỏc s liu thu thp c quỏ trỡnh nghiờn cu 73 bnh nhõn UTPKTBN c iu tr bng Gemcitabin phi hp Cisplatin chỳng tụi cú mt s kt lun nh sau: c im lõm sng v cn lõm sng ca UTPKTBN giai on IV - Bnh nhõn UTPKTBN hay gp tui >40, nh cao t 50 69 tui T l nam/n l 3/1 - Triu chng lõm sng thng gp l au ngc v ho kộo di - V trớ u bờn phi nhiu hn so vi bờn trỏi, typ UTBM tuyn cú t l cao nht (49,3%) Kt qu iu tr v c tớnh ca phỏc - Kt qu iu tr UTPKTBN bnh nhõn giai on IV + T l bnh giai on IV cú th trng cũn tt ỏp ng iu tr bng Gemcitabin v cisplatin l 32,9% + ỏp ng hon ton l = 0%, ỏp ng bỏn phn l: 24/73 = 32,9%, bnh n nh l: 18/73 = 24,7%, bnh tin trin l: 31/73 = 42,5% + Thi gian sng thờm trung bỡnh ca bnh nhõn l 11,5 thỏng (95% CI 10,3 12,5 thỏng) T l sng thờm trung bỡnh nm l 41,7% * ỏnh giỏ c tớnh ca phỏc gemcitabin v cisplatin + T l nụn v bun nụn nghiờn cu ch gp mc l: 63% v l: 21% Khụng cú trng hp no d ng + Gim bch cu a nhõn trung tớnh l ph bin chim 26%, ú mc v ch l 2,7% Gim lng Hb mỏu khỏ ph bin (75,4%) + Khụng cú trng hp no cú suy thn, tỡnh trng tng tng men gan mc v l 17,8% 67 KHUYN NGH - Bnh nhõn UTPKTBN giai on IV nu s dng hoỏ tr thỡ mt nhng phỏc nờn la chn l Gemcitabine - Cisplatin vỡ tớnh an ton v hiu qu - Nờn cú thờm cỏc nghiờn cu tin cu vi c mu ln hn, nhiu bin s hn ỏnh giỏ kt qu iu tr chớnh xỏc hn v thy c cỏc mi liờn quan vi kt qu iu tr TI LIU THAM KHO Nguyn Bỏ c, Nguyn Chn Hựng v cng s (2005) Kt qu bc u nghiờn cu dch t hc mụ t mt s bnh ung th vựng a lý Vit Nam giai on 2001 - 2003 c san ung th hc quý I, Hi phũng chng ung th Vit Nam, trang - Bựi Cụng Ton v Trn Vn Thun (2007) Ung th phi Chn oỏn v iu tr bnh ung th, Nh xut bn Y hc, H Ni, trang 176-187 Globocan I (2012) Cancer incidence, mortality and prevalence, World wide version 1.0, IARC Cancerbase, No.5, Lyon, IARC Press, 2012 T Vn T, Lờ Trung Th v ng Th Cn (2008) Phõn loi mụ bnh hc ung th phi Bnh ung th phi, Nh xut bn Y hc 2008, trang 106 Nguyn Chn Hựng (2012) Tng quan v ung th phi khụng t bo nh Tp Lao v bnh phi, s 7,8 thỏng 2,4/2012, trang 6 Nguyn Bỏ c v o Ngc Phong (2009) Dch t hc bnh ung th, Nh xut bn Y hc 2009 Rudd RM, Gower NH, Spiro SG et al (2005) Gemcitabin plus carboplatin versus mitomycin, ifosfamide, cisplatin in patients with non small cell lung cancer: a phase III randomized study of the London lung cancer group, http://www.ncbi.nlm.nih.gov/pubmed/15625369/downloads Li Y., Wang L R., Chen J et al (2014) First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients Disease markers, 2014 National Comprehensive Cancer Network (2016) Non small cell lung cancer NCCN clinical practice guidelines in oncology v.2.2016, http://www.NCCN.com/downloads 10 Hong Trng Tựng (2006) ỏnh giỏ kt qu iu tr a phng thc ung th phi khụng phi t bo nh giai on IIb, IIIa ti Bnh vin K 2002 - 2006, Lun thc s chuyờn ngnh ung th, Th vin i hc Y H Ni 11 Yun Fan, Neng Ming Lin, Sheng Lin Ma et al (2010) Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer Acta Pharmacol Sin, 2010 Jun 31(6), 746-752 12 Nguyn Bỏ c (2006) Tỡnh hỡnh ung th Vit Nam giai on 2001 2004 qua ghi nhn ung th ti tnh thnh Vit Nam Tp y hc thc hnh, B Y t xut bn, s 541/2006, trang 13 Nguyn Bỏ c (2004) Ung th phi Hoỏ cht iu tr bnh ung th, Nh xut bn Y hc, H Ni, trang 64 - 70 , 289 - 397 14 Nguyn Quc Anh v Ngụ Quý Chõu (2011) Ung th ph qun nguyờn phỏt Hng dn chn oỏn v iu tr bnh ni khoa, Nh xut bn Y hc, H Ni, trang 387-390 15 Bựi Quang Huy (2008) ỏnh giỏ hiu qu iu tr ung th phi khụng phi t bo nh giai on IIIb - IV bng phỏc d Gemcitabin - cisplatin ti bnh vin K, Lun thc s chuyờn ngnh ung th, Th vin i hc Y H Ni 16 V Vn V, ng Thanh Hng v cng s (2001) Hoỏ tr ung th phi nguyờn phỏt ti Trung tõm ung buu thnh ph H Chớ Minh Y hc thnh ph H Chớ Minh s c bit chuyờn ung bu hc, 5, (ph bn s 4), trang 249-253 17 Nguyn Th Minh Hng (2005) ỏnh giỏ kt qu iu tr ung th phi khụng phi t bo nh giai on II, IIIA bng phu thut phi hp x tr hu phu, Lun thc s chuyờn ngnh ung th, Th vin i hc Y H Ni 18 Nguyn Th Hoi Nga, Trn Th Thanh Hng, Phan Thu Hi v cng s (2008) Dch t hc v c ch sinh bnh Bnh ung th phi, Nh xut bn Y hc 2008, trang 7-10 19 Lam W.K, White N.W, Chan Yeung M.M (2004) Lung cancer epidemiology and risk factors in Asia and Africa The International Journal of Tuberculosis and Lung Disease, 8(9), 1045 - 1057 20 Zatloukal P, Petruzelka L, Zemanova M, et al (2002) Gemcitabin carboplatin in advanced non small cell lung cancer, http://www.ncbi.nlm.nih.gov/pubmed/12431827/downloads 21 Nguyn Th Oanh (2015) Nghiờn cu ng dng ni soi ph qun hunh quang chn oỏn ung th ph qun th trung tõm ti bnh vin Phi Trung ng, Lun thc s chuyờn ngnh ung th, Th vin i hc Y H Ni 22 Vincent T, DeVita Jr, Edward Chu A (2008) History of Cancer Chemotherapy Cancer Res, 68;8643 23 Travis W.D, Brambilla E, Burke A.P (2014) WHO classification of tumours of the Lung, Pleura, Thymus and Heart IARC Press 24 Sharwani A, Jerjes W, Salih V (2006) Fluorescence spectroscopy combined with 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in detecting oral premalignancy J Photochem Photobiol B, 83 (1), pp 27-33 25 Nguyn Bỏ c, Trn Vn Thun v Nguyn Tuyt Mai (2010) iu tr ni khoa bnh ung th Nh xut bn Y hc 2010, trang 81 26 Nguyn Vn Hiu v Hong ỡnh Chõn (2010) iu tr phu thut bnh ung th Nh xut bn Y hc, trang 197- 216 27 Kato A., Shimizu H., Ohtsuka M., et al (2015) Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery Annals of surgical oncology, 22 (3), 1093-1099 28 Vừ Vn Xuõn (2001) Ung th ph qun phi Hng dn thc hnh chn oỏn iu tr ung th, Nh xut bn Y hc, H Ni, trang 167-178 29 ng Hong An v Phm Nguyờn Tng (2010) ỏnh giỏ hiu qu húa tr ung th phi khụng t bo nh giai on IIB, IIIA,IIIB ti Bnh vin Trung ng Hu t 2008-2009 Tp ung th hc Vit Nam, s 1/2010, trang 281 30 Bepler G, Kusmartseva I, Sharma S (2006;) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer Journal of Clinical Oncology, 2006: 2024(2029):4731-4737 31 Hoang T, Traynor AM, Schiller JH (2005) Chemotherapy for advanced non-small-cell lung cancer Lung cancer principles and practice, Lippilcott William & Wilkins, 571-587 32 Olaussen KA, Dunant A, Fouret P (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy The New England Journal of Medicine, 2006;2355(2010):2983-2991 33 Li, Jie Jack (2006) Laughing Gas, Viagra, Lipitor: The Human Stories behind the Drugs We Use Oxford University Press, p 34 Motoi N, Szoke J, Riely GJ (2008) Lung adenocarcinoma: modification of the 2004 WHO Mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis Am J Surg Pathol, 32, 810 - 827 35 Martoni A, Marino A, Sperandi F (2005,) Multicentre randomized phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer European Journal of Cancer, 2005, 2041, 2081-2092 36 Belani CP, Lee IS, Socinski MA (2005) Randomized phase III trial comparing Cisplatin - Etoposide to Carboplatin - Paclitaxel in advanced or metastatic non small cell lung cancer Ann Oncol, 16(17), 1069-1075 37 Langer C J., Vangel M., Schiller J et al (2003) O-49 Age-specific subanalysis of ECOG 1594: Fit elderly patietns (7080 yrs) with NSCLC as well as younger patients (< 70) Lung Cancer, 41, S17 38 Joan H Schiller, David Harrington, Chandrap Belani et al (2002) Comparison of four chemotherapy regimens for advanced non small cell lung cancer The New England Journal of Medicine, Vol 346 No.2 January 10, 2002, 92 - 98 39 Gridelli C, Vivo R.De (2002) Vinorelbine in the Treatment of NonSmall Cell Lung Cancer Current Medicinal Chemistry, 879-891(813) 40 Sun J.-M., Ahn J S., Jung S.-H., (2015) Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylated Synthase Expression in Nonsquamous NonSmall-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial Journal of Clinical Oncology, JCO 2014.2059 9324 41 Grigorescu AC, Draghici IN, Nitipir C, et al (2002) Gemcitabin and carboplatin versus cisplatin and vinblastin in advanced non small cell lung cancer: a phase III randomized trial, http://www.ncbi.nlm.nih.gov/pubmed/12057861/downloads 42 Sederholm C (2002) Gemcitabin versus gemcitabin - carboplatin in advanced non small cell lung cancer: preliminary findings in a phase III trial of the Swedish lung cancer study http://www.ncbi.nlm.nih.gov/pubmed/12094340/downloads group, 43 Han J.-Y., Park K., Kim S.-W et al (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in neversmokers with adenocarcinoma of the lung Journal of Clinical Oncology, 30 (10), 1122-1128 44 Rosell R., Carcereny E., Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase trial The lancet oncology, 13 (3), 239-246 45 Paz-Ares L., Socinski M., Shahidi J et al (2016) Correlation of EGFRexpression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabinecisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer Annals of Oncology, mdw214 46 Yatabe Y, Koga T, Mitsudomi T (2004) CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas J Pathol, 203, 645-652 47 Khurum Khan, Gerard G Hanna, Lynn Campbell, et al (2013) Rechallenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer Chin J Cancer, 2013 Oct; 32(10), 539-545 48 Zhang L., Huang Y., Hong S et al (2016) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase trial The Lancet, 49 Jing YF, Wang Y (2008) The development of predicting the lung cancer prognosis and resistance to gemcitabine by the expression level of RRM1 Journal of Clinical Pulmonary Medicine, 2008;2013:1268-1270 50 Karampeazis A., Vamvakas L., Kentepozidis N et al (2016) Biweekly carboplatin plus gemcitabine as first-line treatment of elderly patients with advanced squamous non-small-cell lung cancer: A multicenter phase I-II trial by the Hellenic Oncology Research Group Clinical Lung Cancer, 51 Phan Lờ Thng (2002) Nghiờn cu c iờm lõm sng, mụ bờnh hc ung th phụi nguyờn phỏt ó phõu thuõt ti bờnh viờn K 1999-2001, luõn thc s Y hc, Th vin i hc Y H Ni 52 Saad A S., Ghali R R., Shawki M A (2016) A prospective randomized controlled study of cisplatin versus carboplatin-based regimen in advanced squamous nonsmall cell lung cancer 53 Mok T.S, Wu Y.L, Thongprasert S (2009) Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma N Engl J Med, 361, 947- 957 54 Jan A S., Dolan D E., Lombardi K et al (2016) Tolerability of gemcitabine plus cisplatin for treatment of urothelial cancer in the elderly population Clinical genitourinary cancer, 14 (3), e257-e263 55 Reck M., Socinski M A., Luft A et al (2016) The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase SQUIRE Trial Journal of Thoracic Oncology, 11 (6), 808-818 56 Goldstein N.S, Thomas M (2001) Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies Am J Clin Pathol, 116, 319-325 57 Yoshizawa A, Motoi N, Reily G.J (2011) Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases Modern Pathology, 24, 653-664 58 Tsutsumida H, Nomoto M, Goto M (2007) A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis Mod Pathol, 20, 638-647 59 Lucio Crin, Cesare Calandri, Antonio Maestri et al (2001) Gemcitabine and Cisplatin Combination in Early-Stage Non-Small-Cell Lung Cancer ONCOLOGY, 15(Suppl 6), 40-42 60 Gomez Herrero, Albert Mari A, Merino Sanjuan M Toxicity profile and adherence to the pharmacotherapeutic regimen of gemcitabincarboplatin in non small cell lung cancer, , 61 He Q, Yi T, Zhang L et al Combined chemotheraphy with domestic gemcitabine plus carboplatin in the treatment of advanced non small cell lung cancer, http://www ncbi.nlm.nih.gov/pubmed/21144290/downloads BNH N NGHIấN CU I Phn hnh chớnh S h s: H v tờn: Tui Gii: Nam: N: 2 Ngh nghip: a ch: a ch liờn lc: in thoi liờn lc: Ngy vo vin: Ngy vin: II Thụng tin trc iu tr Lõm sng * Thụng tin chung - Thúi quen hỳt thuc: +Khụng: +C loi: +Thuc lỏ:1 +Tru thuc: +Thuc lo: - S bao:/ ngy S nm: - Lý vo vin: +Ho kộo di: + Khỏihuyt: +au ngc: + Khc m: +Khú th: -Thi gian xut hin triu chng u tiờn n nhp vin: < thỏng: 3-6 thỏng: > thỏng: * Lõm sng: - Triu chng ton thõn: +S da: +Ch s Kanofsky: 70:1 80-90: 100:3 +Cỏc triu chng khỏc: St- Sỳt cõn- Chỏn n - Triu chng hụ hp: +Ho khan:1 cú m:2 m mỏu:3 +Khú th: cú khụng +au ngc: cú khụng +Nc: cú khụng +Nut nghn cú khụng +Khn ting cú khụng +Phự ỏo khoỏc cú khụng +HC Horner cú khụng +Pierre Marie cú khụng +Pancost Tobias cú khụng - Hi chng trn dch mng phi :cú khụng - Hi chng ụng c : khụng - Cỏc hi chng cn u: cú - Hch ngoi biờn : T cựng bờn 1, T i bờn 2, ni khỏc - Triu chng di cn : Gan 1, nóo 2, xng 3, thn 4, phi i bờn Cn lõm sng - V trớ u : Trung tõm I Ngoi biờn II Trờn phi 1, gia phi 2, di phi Trờn trỏi 4, di trỏi -Hch: Khụng 0, rn phi cựng bờn 1, rn phi i bờn Trung tht cựng bờn 3, trung tht i bờn -Xõm ln trung tht 1, xõm ln thnh ngc 2,xõm ln c honh -Trn dch mng phi ỏc tớnh cú khụng XQ CT trc CT sau t CTsau t iu tr iu tr iu tr V trớ Kớch thc Hch Xõm ln TDMP ỏc tớnh - Mụ bnh hc ti u: K biu mụ tuyn K biu mụ vy K biu mụ t bo ln Ti hch Chn oỏn giai on theo TNM Giai on IV 4.iu tr - Liu iu tr >85%